Skip to the page

Data / Drug companies / Marksans Pharma Limited

Marksans Pharma Limited: 62 products in the FDA NDC directory, labeler code 25000

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Marksans Pharma Limited (labeler code 25000) lists 62 products in the FDA National Drug Code Directory, covering 28 finished drugs by generic name. By type: 34 prescription drugs, 28 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 5, 2026.

The request: Watch Marksans Pharma Limited (FDA labeler code 25000): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
25000
Products in commercial distribution
62
Packages
204
Finished drugs by generic name
28
Prescription products
34
Over the counter products
28
Controlled substance products
Schedule V 8
Flagged as original packager
62 of 62 products that carry the flag
Started marketing in the last 12 months
6
Earliest marketing start
February 28, 2011
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)62100%

Products by type

TypeProductsShare
Prescription drugs3454.8%
Over the counter drugs2845.2%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Ibuprofen9190
Pregabalin854
Metformin hydrochloride579
Gabapentin391
Fluoxetine hydrochloride344
Naproxen358
Cetirizine hydrochloride3119
Duloxetine hydrochloride318
Paricalcitol313
Famotidine 20 mg22
Omeprazole 20 mg22
Acetaminophen2214
Guaifenesin 600 mg11
Guaifenesin 1200 mg11
Famotidine 10 mg11
Dutasteride114
Loratadine1125
Loratadine 10mg13
Naproxen sodium, coated tablets11
Esomeprazole magnesium delayed release 20 mg mini11
Acetaminophen 250 mg and ibuprofen 125 mg tablets12
Naproxen sodium tablet, coated11
Benzonatate 100 mg11
Esomeprazole magnesium delayed-release capsules, 20 mg11
Esomeprazole magnesium delayed-release 20 mg (otc)11
Loperamide hydrochloride tablets usp, 2mg11
Benzonatate 200 mg11
Esomeprazole magnesium delayed-release 20 mg mini11

Dosage forms

Dosage formProductsShare
Tablet1930.6%
Capsule1422.6%
Capsule, liquid filled914.5%
Capsule, delayed release711.3%
Tablet, extended release46.5%
Tablet, film coated46.5%
Tablet, coated34.8%
Tablet, delayed release23.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Omeprazole 20 mg25000-094Tablet, delayed releaseGeneric drugs (ANDA)August 5, 2026
Esomeprazole Magnesium Delayed Release 20 mg mini25000-096Capsule, delayed releaseGeneric drugs (ANDA)June 1, 2026
Esomeprazole Magnesium Delayed-Release 20 mg (OTC)25000-088Capsule, delayed releaseGeneric drugs (ANDA)June 1, 2026
Benzonatate 200 mg25000-003Capsule, liquid filledGeneric drugs (ANDA)April 10, 2026
Benzonatate 100 mg25000-002Capsule, liquid filledGeneric drugs (ANDA)April 10, 2026
Loperamide Hydrochloride 2mg25000-001TabletGeneric drugs (ANDA)November 19, 2025
Omeprazole 20 mg25000-091Tablet, delayed releaseGeneric drugs (ANDA)August 12, 2025
Famotidine 20 mg25000-124Tablet, coatedGeneric drugs (ANDA)May 23, 2025
Cetirizine Hydrochloride Tablets, 10 mg (Oval Shape)25000-160TabletGeneric drugs (ANDA)April 10, 2025
Loratadine 10mg25000-092TabletGeneric drugs (ANDA)November 21, 2024
Esomeprazole Magnesium Delayed-Release 20 mg mini25000-112Capsule, delayed releaseGeneric drugs (ANDA)March 18, 2024
Esomeprazole Magnesium Delayed-Release Capsules, 20 mg25000-075Capsule, delayed releaseGeneric drugs (ANDA)September 30, 2023
Guaifenesin 600 mg25000-042TabletGeneric drugs (ANDA)August 23, 2023
Guaifenesin 1200 mg25000-041TabletGeneric drugs (ANDA)August 23, 2023
Acetaminophen 250 mg and Ibuprofen 125 mg25000-080Tablet, film coatedGeneric drugs (ANDA)July 11, 2023
Famotidine 20 mg25000-087Tablet, coatedGeneric drugs (ANDA)March 10, 2023
Famotidine 10 mg25000-086Tablet, coatedGeneric drugs (ANDA)March 10, 2023
Acetaminophen Extended-Release Tablets, 650 mg25000-108Tablet, extended releaseGeneric drugs (ANDA)October 14, 2022
Pregabalin25000-186CapsuleGeneric drugs (ANDA)August 1, 2022
Pregabalin25000-185CapsuleGeneric drugs (ANDA)August 1, 2022
Pregabalin25000-184CapsuleGeneric drugs (ANDA)August 1, 2022
Pregabalin25000-183CapsuleGeneric drugs (ANDA)August 1, 2022
Pregabalin25000-182CapsuleGeneric drugs (ANDA)August 1, 2022
Pregabalin25000-181CapsuleGeneric drugs (ANDA)August 1, 2022
Pregabalin25000-180CapsuleGeneric drugs (ANDA)August 1, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.